|
|
Mannadjuvant |
|
Vaxjo ID |
172 |
|
Vaccine Adjuvant Name |
Mannadjuvant |
|
Adjuvant VO ID |
VO_0005286
|
|
Description |
a carbohydrate, natural compound, combination adjuvant that induces a mixed Th1/Th2 response |
|
Stage of Development |
Research |
|
Location Licensed |
US (Boston Children's Hospital) |
|
Host Species for Testing |
Mouse |
|
Components |
fungal mannans |
|
Storage |
4C |
|
Preparation |
various preparations depending on what extracting mannans from |
|
Function |
Type: combination vaccine adjuvant. Target Receptor: C-type lectin domain family 4 member E (Mincle), C-type lectin domain family 6 member A (Dectin-2). Induces Th1/Th2 mixed immune profile Activates Dectin-2-expressing innate immune cells (injection site and draining lymph node) |
| References |
(Zanoni, 2023): Vaccine Adjuvant Compendium - VAC [https://vac.niaid.nih.gov/view?id=14]
Borriello et al., 2022: Borriello F, Poli V, Shrock E, Spreafico R, Liu X, Pishesha N, Carpenet C, Chou J, Di Gioia M, McGrath ME, Dillen CA, Barrett NA, Lacanfora L, Franco ME, Marongiu L, Iwakura Y, Pucci F, Kruppa MD, Ma Z, Lowman DW, Ensley HE, Nanishi E, Saito Y, O'Meara TR, Seo HS, Dhe-Paganon S, Dowling DJ, Frieman M, Elledge SJ, Levy O, Irvine DJ, Ploegh HL, Williams DL, Zanoni I. An adjuvant strategy enabled by modulation of the physical properties of microbial ligands expands antigen immunogenicity. Cell. 2022; 185(4); 614-629.e21. [PubMed: 35148840].
|
|
